SEMIZLIK BILAN OG'RIGAN BOLALARDA METABOLIK SINDROMNING RIVOJLANISHIDA YY3-36 PEPTIDINING ROLI

TO'LIQ MATN:

Abstrakt

Mazkur maqolada bolalarda oziqlanish xususiyatlarini tartibga solishda yetakchi rol o‘ynaydigan YY-36 peptidini o‘rganish bo‘yicha ma'lumotlar keltirilgan. Ushbu peptid ingichka va yo‘g‘on ichakning distal qismidagi L-hujayralar tomonidan sintezlanadi, ovqat qabul qilingandan so‘ng qonga tushadi va anoreksigen gormon hisoblanadi. Tadqiqot natijalari pediatr shifokorlar, umumiy amaliyot shifokorlari va bolalar endokrinologlari amaliy faoliyatiga keng joriy etish uchun tavsiya etiladi. Tadqiqot maqsadi: Semizlik fonida bolalarda metabolik sindrom rivojlanishida YY3-36 peptidining rolini aniqlash. Materiallar va usullar: yog‘ massasi abdominal tipda taqsimlangan, yoshi va jinsi bo‘yicha bel aylanasi 90-percentildan yuqori ekzogen-konstitutsional semizligi bo’lgan 108 nafar bola tekshirildi. Taqqoslash uchun tana vazni normal bo‘lgan 76 nafar bola o‘rganildi. Antropometrik, biokimyoviy, immunoferment tadqiqotlar o‘tkazildi, qon zardobida YY3-36 peptidi darajasi aniqlandi. Metabolik sindrom tashxisi mezonlariga ko‘ra abdominal tipdagi semizligi bo’lgan bolalarda metabolik sindrom uchrash chastotasi, uning shakllari va kombinatsiyalari baholandi. Tadqiqot natijalari: Semizligi bo’lgan bolalarda YY3-36 peptidi darajasini o‘rganishda abdominal tipdagi semizlikli bolalarda uning sezilarli darajada pastligi (72,13 pg/ml) aniqlanib, bu ko‘rsatkich nazorat guruhiga nisbatan ancha past bo‘ldi (105,39 pg/ml; r<0,001). Ichak neyroregulyator peptidi YY3-36 ishlab chiqarilishining jinsiy farqlarini baholashda o‘g‘il bolalarda darajaning yanada pasayishi kuzatildi, bu esa visseral yog‘ to‘planishi fonida o‘g‘il bolalarda peptid ishlab chiqarilishining kuchliroq buzilganligini ko‘rsatdi. Tadqiqotda bolaning yoshi oshishi bilan peptid darajasi pasayish tendensiyasi qayd etildi; 16–18 yoshli bolalarda YY3-36 darajasi 10–15 yoshli bolalarga qaraganda pastroq bo‘ldi. Nazorat guruhida bunday yoshga oid dinamika kuzatilmadi. Abdominal semizlik davomiyligi oshishi bilan ichak neyroregulyator peptid YY3-36 darajasi bosqichma-bosqich kamayishi aniqlanib, bu ehtimoliy ravishda ovqatlanish xususiyatlarining buzilishining kuchayishi bilan bog‘liq bo’ldi. Abdominal semizligi bo’lgan barcha bolalarda YY3-36 darajasi past bo‘lib, bu metabolik sindrom shakllanishida ovqatlanish xususiyatlarining buzilishi muhim omil ekanligini ko‘rsatdi; eng past ko‘rsatkichlar to‘liq metabolik sindromli bolalarda qayd etildi. Hozirgi paytda YY3-36 darajasini patologik holatlarni, jumladan, semizligi bo’lgan bolalardagi metabolik sindromni diagnostika qilish mezoni sifatida talqin qilish bo‘yicha aniq mezonlar mavjud emas. Shu sababli abdominal semizligi bo’lgan bolalarda metabolik sindrom diagnostikasida YY3-36 peptidining chegaraviy daragasi aniqlandi. AUC-ROC tahlilida peptid YY3-36 darajasining AUC maydoni ≤71,600 bo‘lgan chegaraviy qiymatda sezilarli diagnostik darajaga erishdi: sezgirlik 84,2% va spetsifiklik 73,4% (AUC=0,856). Xulosalar: Tadqiqotlar YY3-36 peptidi ishlab chiqarilishining buzilishi bolalarda abdominal semizlik rivojlanishiga sezilarli ta'sir ko‘rsatishini ko‘rsatdi. O‘tkazilgan ish metabolik sindrom bo’lgan bolalarda ushbu ovqatlanish gormonining ishlab chiqarilishi keskin kamayishini tasdiqladi, bunda eng yuqori darajadagi buzilish to‘liq metabolik sindromga ega o‘g‘il bolalarda kuzatildi.

Mualliflar haqida

Adabiyotlar ro'yxati

Xin’nan Zong, Pascal Bovet, Bo Xi A Proposal to Unify the Definition of the Metabolic Syndrome in Children and Adolescents. Front. Endocrinol., Sec. Pediatric Endocrinology. 2022; 13: https://doi.org/10.3389/fendo.2022.925976

Kadıoğlu Yılmaz B, Akgül AH. Inherited Metabolic Diseases from Past to Present: A Bibliometric Analysis (1968–2023). Children. 2023; 10(7):1205. https://doi.org/10.3390/children10071205

Boucsein, A., Zhou, Y., Haszard, J.J. et al. Protocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed lOoP In chiLdren and y Outh with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trial. J Diabetes Metab Disord 23, 1397-1407 (2024). https://doi.org/10.1007/s40200-024-01397-4

Reisinger C. et al. The prevalence of pediatric metabolic syndrome-a critical look on the discrepancies between definitions and its clinical importance. Int. J. Obes. 45(1), 12-24 (2021)

Khavkin A.I., Airumov V.A., Shvedkina N.O., Novikova V.P. Biological role and clinical significance of neuropeptides in pediatrics: peptide YY and ghrelin. Issues of practical pediatrics, 2020; 15(5):87-92 (in Russian)

Boey D., Lin S., Karl T. et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2016; 49: 6: 1360-1370

Tam, F.I., Seidel, M., Boehm, I. et al. Peptide YY3–36 concentration in acute- and long-term recovered anorexia nervosa. Eur J Nutr 59, 3791–3799 (2020). https://doi.org/10.1007/s00394-020-02210-7

Xu J., Mc Nearney T.A., Chen J. Impaired postprandial releases/ syntheses of ghrelin and PYY (3-36) and blunted responses to exogenous ghrelin and PYY (3-36) in a rodent model of diet-induced obesity. J Gastroenterol Hepatol 2011; 26: 4: 700-705.

Dalia E.l., Khoury D., Rola El-Rassi R., Azar S., Hwalla N. Postprandial grelin and PYY responses of male subjects on low carbohydrate meals to varied balancing proportions of proteins and fats. Eur J Nutr 2019; 49: 8: 493-500

World Health Organisation. WHO Child growth standarts: Methods and development. Geneva: WHO; 2017

Peterkova V.A., Bezlepkina O.B., Vasyukova O.V. et al. Obesity in children. Clinical guidelines. Moscow: Ministry of Health of the Russian Federation; 2021. 77 p. (in Russian)

Zimmet P. et al. The metabolic syndrome in children and adolescents. Lancet 2007; 369(9579): 2059-206.

Helou N., Obeid O., Azar S.T. et al. Variation of postprandial PYY3-36 response following ingestion of diff ering macronutrient meals in obese females. Ann Nutr Metab 2018; 52: 3: 188-195

Berezina A.E. Diagnostic informativeness and prognostic value of intestinal regulatory neuropeptides in patients with metabolic syndrome // UKR. MED. CHASOPIS, 2013; 1(93): 23-28 (in Russian)

Tyszkiewicz-Nwafor, M.; Jowik, K.; Dutkiewicz, A.; Krasinska, A.; Pytlinska, N.; Dmitrzak-Weglarz, M.; Suminska, M.; Pruciak, A.; Skowronska, B.; Slopien, A. Neuropeptide Y and Peptide YY in Association with Depressive Symptoms and Eating Behaviours in Adolescents across the Weight Spectrum: From Anorexia Nervosa to Obesity. Nutrients 2021, 13, 598. https://doi.org/10.3390/nu13020598

Qanday qilib iqtibos keltirish kerak

Garifulina Л., & Rustamov У. (2025). SEMIZLIK BILAN OG’RIGAN BOLALARDA METABOLIK SINDROMNING RIVOJLANISHIDA YY3-36 PEPTIDINING ROLI. Xalqaro Ilmiy Pediatriya Jurnali, 4(5), 1126–1132. https://doi.org/10.56121/2181-2926-2025-4-5-1126-1132
Ko'rishlar soni: 0

Ushbu muallif(lar)ning eng koʻp oʻqilgan maqolalari